CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
The Canadian Cancer Trials Group's (CCTG) Head and Neck Executive Committee (HNEC) is currently seeking individuals with interest and experience in head and neck studies to join the HNEC. In broad terms (adapted from the CCTG's Terms of Reference), the roles of the Disease Site Committee (DSC) Executive members are to:
Carol is a cancer survivor who was treated for metastatic gynecologic cancer in 2013. She has a network of other cancer survivors and patients who support each other during their cancer journeys. Today, Carol is currently a CCTG patient representative for the CCTG Gynecology, Economic Analysis and Clinical Trials committees. Carol is also the Managing Director, Audit Services at Ontario Teachers Pension Plan. Her career has included roles in finance, information technology, investments, risk management, external audit and (now) internal audit.
The Canadian Cancer Trials Group is seeking a Physician trained in a cancer-related specialty to join our research group as a Senior Investigator in the Investigational New Drug (IND) Program.
Dr. Michael McKenzie is a radiation oncologist with extensive experience in genitourinary oncology, neurooncology and palliative oncology at the BC Cancer Agency (BCCA), Vancouver Cancer Centre, and a Clinical Professor in the Division of Radiation Oncology and Developmental Radiotherapeutics at University of British Columbia. He works with patients with genitourinary cancers and brain tumours. He has served as Chair of BCCA’s Palliative Care Network.
It is with great sadness that CCTG shares the news of the passing of Aldo Del Col, a valued member of the CCTG Patient Representative Committee and the Hematology Disease Site Committee. He worked tirelessly to ensure that the patient voice was part of the design and conduct of CCTG clinical trials.
The Pharmacist Network is actively seeking a volunteer as Pharmacist Representative for the Lung Disease Site Committee.
The Pharmacist Disease Site Committee representative is expected to represent the perspective of the Pharmacist community during discussion of potential new studies and ongoing trials. Please review terms of reference at: Pharmacist Representatives on Disease Site Committees
The Award
In recognition of the critical role played by the CCTG throughout her professional career, Dr. Shepherd is giving back by sharing her Gairdner Award with the CCTG. This award, to be endowed in perpetuity, will recognize excellence in clinical trials and translational research and will be open to all qualified CCTG investigators and post graduate trainees working on CCTG research projects.Each award will be $1000 and offered twice a year.
Eligibility
Three new publications from the CCTG Committee on Economic Analysis
